Acumen Pharmaceuticals (ABOS) vs Korro Bio (KRRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Acumen Pharmaceuticals (ABOS) has outperformed Korro Bio (KRRO) over the past year, gaining 11.7% versus a loss of 78.5%. Over five years, ABOS leads with a -84.5% price change compared with -97.0% for KRRO. Korro Bio is the larger company by market cap ($150.6 million vs $148.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | KRRO |
|---|---|---|
| Share price | $2.05 | $10.23 |
| Market cap | $148.25M | $150.64M |
| 1-day change | -2.38% | -2.45% |
| YTD return | -0.47% | +30.96% |
| 1-year return | +11.70% | -78.49% |
| 5-year return | -84.50% | -97.05% |
| EPS (TTM) | $-1.64 | $-9.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.60 | $55.89 |
| 52-week low | $1.50 | $5.20 |
| Distance from 52-week high | -43.06% | -81.70% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +270.73% | +97.46% |
| Average volume | 435.44K | 148.80K |
| Shares outstanding | 72.32M | 14.73M |
| Employees | 60 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABOS has outperformed KRRO by 90.2 percentage points over the past year.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
About Korro Bio
KRRO stock →Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
ABOS vs KRRO FAQ
Which is bigger, Acumen Pharmaceuticals or Korro Bio?
Korro Bio (KRRO) is larger, with a market capitalization of $150.64M compared with $148.25M for Acumen Pharmaceuticals (ABOS).
Which stock has performed better over the past year, ABOS or KRRO?
ABOS returned +11.70% over the past 12 months, compared with -78.49% for KRRO (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and Korro Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Acumen Pharmaceuticals and Biotechnology: Pharmaceutical Preparations for Korro Bio.